These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization. Ahn SJ; Park KH; Woo SJ Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418 [TBL] [Abstract][Full Text] [Related]
4. Subfoveal choroidal thickness as a potential predictor of visual outcome and treatment response after intravitreal ranibizumab injections for typical exudative age-related macular degeneration. Kang HM; Kwon HJ; Yi JH; Lee CS; Lee SC Am J Ophthalmol; 2014 May; 157(5):1013-21. PubMed ID: 24487050 [TBL] [Abstract][Full Text] [Related]
5. Subfoveal choroidal thickness changes after intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation. Maruko I; Iida T; Oyamada H; Sugano Y; Saito M; Sekiryu T Retina; 2015 Apr; 35(4):648-54. PubMed ID: 25627088 [TBL] [Abstract][Full Text] [Related]
6. Subfoveal choroidal thickness in idiopathic choroidal neovascularization and treatment outcomes after intravitreal bevacizumab therapy. Kim H; Lee K; Lee CS; Byeon SH; Lee SC Retina; 2015 Mar; 35(3):481-6. PubMed ID: 25313710 [TBL] [Abstract][Full Text] [Related]
7. Intravitreal ranibizumab for pigment epithelium detachment with subfoveal occult choroidal neovascularization: a prospective 24-month case series. Parodi MB; Iacono P; Papayannis A; Kontadakis SD; Cascavilla M; Pierro L; Gagliardi M; Bandello F Am J Ophthalmol; 2013 Jan; 155(1):103-108.e2. PubMed ID: 23022164 [TBL] [Abstract][Full Text] [Related]
8. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results. Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967 [TBL] [Abstract][Full Text] [Related]
9. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab. Yang HS; Kim JG; Kim JT; Joe SG Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429 [TBL] [Abstract][Full Text] [Related]
10. Baseline choroidal thickness as a predictor for response to anti-vascular endothelial growth factor therapy in diabetic macular edema. Rayess N; Rahimy E; Ying GS; Bagheri N; Ho AC; Regillo CD; Vander JF; Hsu J Am J Ophthalmol; 2015 Jan; 159(1):85-91.e1-3. PubMed ID: 25261844 [TBL] [Abstract][Full Text] [Related]
11. Changes in Choroidal Thickness After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor in Pachychoroid Neovasculopathy. Padrón-Pérez N; Arias L; Rubio M; Lorenzo D; García-Bru P; Català-Mora J; Caminal JM Invest Ophthalmol Vis Sci; 2018 Feb; 59(2):1119-1124. PubMed ID: 29490349 [TBL] [Abstract][Full Text] [Related]
12. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection. Saito M; Kano M; Itagaki K; Ise S; Imaizumi K; Sekiryu T Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229 [TBL] [Abstract][Full Text] [Related]
13. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration. Shin JY; Kwon KY; Byeon SH Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639 [TBL] [Abstract][Full Text] [Related]
14. Association between choroidal morphology and anti-vascular endothelial growth factor treatment outcome in myopic choroidal neovascularization. Ahn SJ; Woo SJ; Kim KE; Park KH Invest Ophthalmol Vis Sci; 2013 Mar; 54(3):2115-22. PubMed ID: 23462751 [TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab for treatment of subfoveal idiopathic choroidal neovascularization: results of a 1-year prospective trial. Zhang H; Liu ZL; Sun P; Gu F Am J Ophthalmol; 2012 Feb; 153(2):300-306.e1. PubMed ID: 21982109 [TBL] [Abstract][Full Text] [Related]
16. Relation between changes in foveal choroidal thickness and 1-year results of ranibizumab therapy for polypoidal choroidal vasculopathy. Hikichi T; Kitamei H; Shioya S; Higuchi M; Matsushita T; Kosaka S; Matsushita R; Takami K; Ohtsuka H Br J Ophthalmol; 2014 Sep; 98(9):1201-4. PubMed ID: 24723615 [TBL] [Abstract][Full Text] [Related]
18. Intravitreal ranibizumab therapy versus photodynamic therapy for idiopathic choroidal neovascularization: a comparative study on visual acuity, retinal and choroidal thickness. Shi X; Wei W; Zhang C Chin Med J (Engl); 2014; 127(12):2279-85. PubMed ID: 24931242 [TBL] [Abstract][Full Text] [Related]
19. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Rouvas A; Petrou P; Douvali M; Ntouraki A; Vergados I; Georgalas I; Markomichelakis N Retina; 2011 May; 31(5):871-9. PubMed ID: 21358461 [TBL] [Abstract][Full Text] [Related]
20. Subfoveal choroidal thickness in idiopathic choroidal neovascularization. Ahn SJ; Kim TW; Ahn J; Woo SJ; Park KH; Lee BR Ophthalmology; 2014 Jul; 121(7):1486-7.e2. PubMed ID: 24793527 [No Abstract] [Full Text] [Related] [Next] [New Search]